Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...
TipRanks on MSN
Contineum Therapeutics Reports Phase 2 Trial Results
Contineum Therapeutics, Inc. Class A ( ($CTNM) ) has shared an update. On November 20, 2025, Contineum Therapeutics reported topline data from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback